Payer Site-of-Care Redirection Programs and Revenue Impact

Payer site-of-care redirection programs change more than where patients receive infusions. They change the conditions under which practices get paid, from drug purchasing to authorization and payment review. To protect revenue, the billing team must link those decisions before treatment and track each claim even after it is paid.

How payer site-of-care redirection programs work and what drives them

Payers use site-of-care rules to steer infusions away from hospital outpatient departments when they consider a lower-cost setting clinically appropriate. They can deny hospital reimbursement, limit the rate, or require prior authorization that directs the patient elsewhere. Some programs require a move to home or ambulatory care after initial treatment. Others reach out to patients and offer them financial incentives to switch. Site selection is now part of utilization management.

These programs are already operating at major payers. Arunkumar Krishnan’s July 2026 JCO Oncology Practice framework describes UnitedHealthcare and Aetna policies that restrict hospital outpatient reimbursement when a lower-cost ambulatory alternative is available. Excellus BCBS Policy PHARMACY-118 establishes medical necessity criteria for outpatient hospital-based administration. It took effect in October 2024 for select self-funded plans and January 2025 for specified fully insured plans. Under that structure, the hospital setting requires affirmative justification.

The direction extends beyond commercial payer restrictions. CMS increased reimbursement rates for professional services under its Home Infusion Therapy Services benefit in 2025, although it did not structurally expand the benefit. Because the restrictions sit within standing policies, they are harder to challenge patient by patient than an isolated coverage decision.

What redirection actually does to an infusion practice's revenue structure

For an infusion practice, the first financial change may be the loss of drug margin on retained patient volume. Under buy-and-bill, the practice purchases the drug and receives reimbursement for it, with drug procurement and administration margins driving the economics. Medicare Part B reimburses at ASP plus a statutory add-on percentage. Drug reimbursement minus acquisition cost is the drug margin. When white bagging replaces buy-and-bill, an external specialty pharmacy supplies the drug, leaving the practice with administration fees alone.

That change can alter the value of retained volume. The framework notes that a program with 340B designation sacrifices its drug discount margin when it partners with a non-340B platform. Moving treatment is therefore also a drug economics decision. A financial model focused only on visits or professional fees misses that change. The same number of infusions can produce a different revenue structure when the acquisition model changes.

Volume itself can also leave the practice. The framework calls the shift “not a gradual volume shift; it is a structural redirection” and values the ambulatory infusion center market at $51 billion in 2025, with oncology its largest category. Practices must compete for that volume without the capacity to provide ambulatory care or the processes to meet payer requirements. At the same time, practices need more documentation for patients who stay under clinical exceptions. The Excellus policy allows hospital maintenance administration of immune checkpoint inhibitors for patients under 18 or those receiving concurrent cytotoxic chemotherapy at the same visit. Separately, defined clinical instability can qualify a patient receiving any covered drug, so the record must support the applicable exception.

Why the authorization process is the first point where redirection revenue risk is won or lost

Before treatment, the practice must establish active insurance coverage, authorization for the drug and administration service, and coverage at the specific facility type. It must also confirm the payer’s requirements for white bagging or permission to use buy-and-bill. These are separate conditions of payment, even when they concern the same visit. A clinical justification does not resolve a denial caused by using the wrong acquisition model.

The costly trap is an approval that looks complete but is not. A practice may obtain authorization for the therapy, purchase the drug, and administer it without separately confirming that the setting is covered for that patient. The denial then arrives after the expense has been incurred. At that point, a preventable coverage failure may no longer be recoverable. Site-of-care verification must be part of scheduling and authorization, before the drug is ordered.

Recurring treatment requires a continuing workflow because authorizations can run out mid-cycle, and step therapy requirements may call for proof that earlier treatments failed. Clinical criteria can require lab values, imaging, specialist notes, and treatment histories assembled in payer-specific formats. The Excellus policy also updates its covered drug list quarterly. A therapy approved for hospital administration last quarter may fall under redirection criteria this quarter if it has been added to that list. Renewal management therefore needs to track both the patient’s authorization and changes in the policy behind it.

How payer-specific denial patterns under redirection programs require differentiated responses

Even a well-managed authorization process does not eliminate claim denials. Calling every related rejection a “site-of-care denial” hides distinctions between a setting restriction, an authorization mismatch, a coding problem, and a failure to document a clinical exception. Those distinctions determine what an appeal must establish. A generic medical necessity letter cannot answer every kind of payment objection.

UnitedHealthcare and Aetna use network architecture and prior authorization requirements in their site-of-care restrictions. The Excellus policy instead sets out defined medical necessity exceptions and a quarterly-updated drug list. An appeal under that policy must show how the patient meets a medical necessity exception as well as why the patient needs the therapy. A denial tied to a modifier also needs a different response from one based on medical necessity, even when both occur during a shift under redirection.

Automated adjudication makes documentation alignment more consequential. Payers can check clinical notes against the CPT and diagnosis codes on the claim before a person reviews it, so gaps can lead to automatic denials. That does not mean every initial denial is valid. The operational response is to categorize denials by payer and root cause, then use the channel and evidence suited to each one. Repeated site-of-care denials should also guide authorization work because they can point to a missed check before treatment, even when they look like separate billing exceptions.

J-code and drug acquisition complexity that redirection programs layer onto existing billing risk

A practice may move between buy-and-bill and white bagging as payer requirements change, while its billing setup still reflects the earlier arrangement. That mismatch creates claim-level risk even when the therapy itself is authorized. When a drug’s acquisition model changes mid-authorization cycle, the practice needs to review how it bills for that drug. Otherwise, the claim can reflect the wrong purchasing pathway.

White bagging also requires close attention to the drug supplied by the external specialty pharmacy. The practice must reconcile the NDC, exact strength dispensed, and administered units with the J-code information reported on the claim. A mismatch can produce either a denial or an underpayment. Errors in units can cost a great deal with high-dose biologics. If the same error recurs across weekly infusions, the revenue loss compounds without any change in patient volume.

Code maintenance adds another moving part. CMS rejects claims that use discontinued HCPCS codes effective January 1, 2026, so billing systems and charge masters need updates each quarter. New biologics can also reach the Part B buy-and-bill market before they have a permanent J-code, requiring NOC or temporary Q-codes. During that time, reimbursement is based on WAC until ASP data catches up, usually two quarters later, and the payment can be less than the acquisition cost. Redirection adds acquisition-model changes to the coding and reimbursement uncertainty the billing team already manages.

How underpayments generated by redirection-adjusted claims become permanent write-offs without active remittance review

A paid claim can still lose revenue. Claims adjusted for redirection may be paid at a rate that differs from the contracted or expected amount without ever reaching a denial queue. If the practice posts the payment and writes off the difference without reviewing each line, the shortfall disappears into routine billing work. Exposing the shortfall requires checking whether the drug and service were paid at the rates due.

A site-of-care differential shows how this happens. A payer may apply an ambulatory rate even though the service was delivered in a setting entitled to a higher rate. The remittance records a payment, so standard denial tracking has nothing to flag. The framework notes that standard infusion financial models can miss the drug margin differential. The same blind spot affects payment review when the practice does not reconcile reimbursement at the drug-and-rate level.

Payment is not necessarily the end of adjudication, either. Post-payment recoupments can arrive months after a claim appeared settled, including takebacks based on a later finding that hospital-site clinical criteria were not met. A billing team that has closed the claim may miss the opportunity to dispute that finding. The response is line-level remittance reconciliation within payment posting, with underpayments flagged before write-off and recoupments tracked within the appeal window. When the accounts receivable process tracks only total balances or zero-pay claims, much of this loss goes unseen.

What an infusion practice's revenue cycle operation must be able to do differently when redirection programs are active

Knowing a payer’s site-of-care rule is useful only if that rule changes what happens at scheduling, authorization, drug ordering, claim submission, and payment review. The practice must link drug authorization with facility approval and include acquisition requirements in the billing workflow.

Staff must verify the site before treatment and track each payer’s authorization along with the acquisition model it requires. Quarterly policy monitoring must cover drug lists, clinical criteria, and HCPCS changes so that staff are not applying a superseded rule. Staff who handle denials need different responses for setting restrictions, authorization mismatches, medical necessity challenges, and acquisition conflicts. Staff must review payment for each claim line and keep tracking any later recoupments. Findings from both processes should return to scheduling and authorization so recurring errors are corrected at their source.

These connections are specific to infusion and buy-and-bill. A general-purpose billing system does not handle the interdependencies between site-of-care policy, drug acquisition, J-code accuracy, and payment simply by tracking claim status. The needed operating model combines software with experienced operators who can manage those dependencies throughout the authorization and billing lifecycle. The work must prevent avoidable losses before treatment and identify recoverable losses afterward.

The competitive pressure makes that work urgent. The ambulatory infusion center market is growing at a 10.6% compound annual growth rate through 2030, while private equity is consolidating independent infusion capacity and major payers are executing redirection programs at scale. Practices that do not adapt risk ceding both volume and margin to better-positioned competitors.